Mirko Bibl
Von Siebold Str. 5
Goettingen, NI 37075, Germany
Goettingen, NI 37075, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Correction to: Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia.
Journal: Journal of neural transmission (Vienna, Austria : 1996)
Published: August 31, 2018
Neurochemical biomarkers in Alzheimer's disease and related disorders.
Journal: Therapeutic advances in neurological disorders
Published: November 10, 2012
Plasma amyloid-beta peptides in acute cerebral ischemia: a pilot study.
Journal: Journal of clinical laboratory analysis
Published: July 20, 2012
Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-β peptides.
Journal: Proteomics. Clinical applications
Published: April 26, 2012
Aminoterminally truncated and oxidized amyloid-β peptides in the cerebrospinal fluid of Alzheimer's disease patients.
Journal: Journal of Alzheimer's disease : JAD
Published: March 31, 2012
Stability of amyloid-β peptides in plasma and serum.
Journal: Electrophoresis
Published: January 31, 2012
Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia.
Journal: Journal of neural transmission (Vienna, Austria : 1996)
Published: January 21, 2012
Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.
Journal: Dementia and geriatric cognitive disorders
Published: October 22, 2010
Showing 1-8 of 8
Last Updated: 09/26/2026